The IPO subscription for Nexteye has fully concluded with the second day of the schedule. As the equal allocation exceeded 10 shares, investors' attention is now turning to the stock's price movement after its listing on the 12th.

Subscription Results... Equal Allocation of 10.97 Shares, Proportional Competition Ratio of 25.52 to 1

Nexteye conducted its general investor subscription through Korea Investment & Securities over two days, from the 3rd to the 4th.

The total number of collected subscription applications was 56,990, resulting in an equal allocation of 10.97 shares. The proportional competition ratio was recorded at 25.52 to 1.

A New Drug Development Company Targeting Immunotherapy Resistance

Nexteye is a company whose main business is developing anticancer drugs. According to its regulatory filing, Nexteye is a new drug development company that identifies causative factors of immunotherapy resistance and develops anticancer drugs targeting them. Attention is also focused on how its related businesses will unfold going forward.

Listing D-Day in Focus... Supply and Demand on the First Trading Day Is the Key Watch Point

With the subscription schedule concluded, market attention is shifting to the listing day. Nexteye is scheduled to list on November 12th.

With the equal allocation reaching the 10-share range and the proportional competition ratio tallied at 25.52 to 1, the key point to watch is how the stock price moves on listing day. In particular, since the figures shown during the subscription process and the actual stock price formed in the market after listing are separate matters, it is necessary to monitor the supply-demand dynamics and price movements on the first trading day.

Interest in the IPO market is expected to continue regarding what kind of start Nexteye will make after entering the stock market on the 12th.

[※ This article is for reference in making investment decisions, and the final responsibility for investments lies with the investor.]